2025 EQA Price List

(includes EQAs from 1st April 2025 - 31st March 2026)

For 2025*, GenQA are delighted to offer 124 genomics external quality assessments (EQA) covering thirteen different disciplines which encompass the sample and patient journey. In addition, we are offering several assessments for individual competency.

*Some 2024 EQAs which are due to be distributed between September 2024-January 2025 may still be open for enrolment.

Early bird discounts are available on orders placed before 31st January 2025.

Further information for 2025 EQAs can be found:

- Click on the **code** associated with each EQA listed below
- In depth details for each EQA: www.genqa.org/eqa
- Available individual competency assessments: www.genqa.org/genie
- New and updated EQAs for 2025: www.genqa.org/2025
- EQA distribution/assessment dates: www.genqa.org/calendar

If you have any questions regarding membership or enrolment, please email info@genqa.org.

For full details of all EQA offered go to www.genqa.org/eqa

Please browse this directory and contact us at info@genqa.org if you require any further information.

Clinical Genetics & Genetic Counselling

Enrol in any 4 Clinical Genetics EQAs (CGC, CGD, CGM, CGO, CGU) and get a Genetic counselling EQA (CGGR or CGGO) for FREE!

External Quality Assessment (EQA)	Code	Sample	Status	£
Clinical Genetics - cardiovascular disorders Clinical diagnosis and genetic counselling based on family history and test results of cardiovascular disorders with a genetic aetiology.	CGC	Case scenario	2	160
Clinical Genetics - dysmorphology Clinical diagnosis and genetic counselling based on family history and test results of syndromes involving dysmorphism with a genetic aetiology.	CGD	Case scenario	2	160
Clinical Genetics - inherited metabolic disorders Clinical diagnosis and genetic counselling based on family history and test results of metabolic disorders with a genetic aetiology.	CGU	Case scenario	3	160
Clinical Genetics - monogenic disorders Clinical diagnosis and genetic counselling based on family history and test results of syndromes involving single gene(s) disorders.	CGM	Case scenario	2	160
Clinical Genetics - oncogenetics Clinical diagnosis and genetic counselling based on family history and test results of cancers with a genetic predisposition or inherited.	CGO	Case scenario	2	160
Genetic counselling - oncogenetics UPDATED Pre and post test counselling for various cancers with a genetic predisposition or inherited. Based on family history and test results.	CGGO	Case scenario	3	160
Genetic counselling - rare and inherited disorders UPDATED Pre and post test counselling for prenatal diagnosis, and rare and inherited genetic disorders/diseases. Based on family history and test results.	CGGR	Case scenario	3	160

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
£: standard cost

For full details of all EQA offered go to www.genqa.org/eqa
Please browse this directory and contact us at info@genqa.org if you require any further information.

Genomic and Inherited disorders

Enrol in 10 Genomic and Inherited disorders accredited EQAs - Save £100!
Enrol in 15 Genomic and Inherited disorders accredited EQAs - Save £250!
Enrol in 20 Genomic and Inherited disorders accredited EQAs - Save £500!

External Quality Assessment (EQA)	Code	Sample	Status	£
Ataxia & Hereditary Spastic Paraplegia (HSP) Friedreich ataxia, spinocerebellar ataxia and hereditary spastic paraplegia	GATAX	DNA	1	395
Calcium disorders Hypercalcaemia and hypocalcaemia including: Familial hypoparathyroidism, Albright hereditary osteodystrophy, Pseudohypoparathyroidism, Pseudopseudohypoparathyroidism, Isolated hyperparathyroidism, Hypocalciuric hypercalcaemia, Calcium sensing receptor phenotypes	GCAL	Case scenario	1	255
Cardiac disorders Arrythmias: Brugada syndrome, Long QT syndrome, Catecholaminergic polymorphic ventricular tachycardia (CPVT) and Progressive cardiac conduction disease. Cardiomyopathies: Hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic ventricular cardiomyopathies and paediatric cardiomyopathy. Syndromic aortopathies: Marfan syndrome, Ehlers Danlos syndrome and Loeys Dietz syndrome. Non syndromic aortopathy.	GCARD	DNA	1	395
Charcot Marie Tooth disease and related sensory and motor neuropathies Charcot Marie Tooth disease (CMT) and Hereditary Liability to Pressure Palsies (HNPP), including *PMP22*, *GJB1*, *MPZ*, *MFN2* and other associated genes	GCMT	DNA	1	395
Chromosome instability syndromes[a] Ataxia telangiectasia, Bloom syndrome, Cornelia de Lange syndrome, Fanconi anaemia, ICR, syndrome, mosaic variegated aneuploidy, Nijmegen syndrome, Roberts syndrome and Seckel syndrome	GCI	Images and DNA	1	395
Cystic fibrosis and *CFTR*-related disorders Cystic fibrosis, Bronchiectasis, CBAVD	GCF	DNA	1	395
Developmental Delay[a] Interpretation of genetic causes of developmental delay, includes molecular and cytogenomic test results	GDD	Case scenario	1	395
Differences in Sex Development (DSD)[a] Androgen insensitivity syndrome, Congenital adrenal hyperplasia, Congenital adrenal hypoplasia, 5-alpha-reductase deficiency, cytogenomic abnormalities and other disorders associated with a DSD NGS panel	GDSD	Case scenario	1	395
Epilepsy disorders Monogenic epilepsies and genetic epilepsy syndromes including: Tuberous sclerosis, Rett syndrome and Dravet syndrome.	GEP	DNA	1	395
Eye disorders Retinopathies, structural eye disorders, optic atrophy, cataracts and albinism	GEYE	Case scenario	1	255
Familial colorectal cancer and polyposis Lynch syndrome, Familial Adenomatous Polyposis and *MUTYH*-associated Polyposis (MAP)	GCRC	DNA	1	395

Genomic and Inherited disorders

External Quality Assessment (EQA)	Code	Sample	Status	£
Familial endocrine tumour predisposition disorders *MEN1,* MEN2, *VHL* and FMTC disorders	GEND	Case scenario	1	255
Familial Hypercholesterolaemia *LDLR*, *APOB* and *PCSK9*	GFH	Case scenario	1	255
Fragile X syndrome and *FMR1*-related disorders Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome, Premature ovarian failure (POF)	GFRAX	DNA	1	395
Gastroenterology and hepatology disorders Hereditary Pancreatitis, Gilbert syndrome, Cholestasis, Hirschsprung disease, Polycystic liver disease.	GGH	DNA	1	395
Hereditary Breast and Ovarian Cancer (HBOC) disorders Familial Breast and Ovarian Cancer (*BRCA1* and *BRCA2*), Cowden Syndrome and Li-Fraumeni	GHBOC	DNA	1	395
Huntington disease (HD) and DRPLA	GHD	DNA	1	395
Hypotonic Infant[a] Spinal Muscular Atrophy type 1 (SMA), Prader Willi Syndrome (PWS) and Myotonic Dystrophy type 1 (DM1)	GHI	DNA	1	395
Imprinting disorders[a] Angelman Syndrome (AS), Beckwith-Wiedemann Syndrome (BWS), Silver Russell Syndrome (SRS), Wilms tumour and Temple syndrome	GIM	DNA	1	395
Inborn errors of metabolism (IEM) MCADD, Fabry disease, galactosaemia and lysosomal storage disease	GIEM	DNA	1	395
Infertility[a] Chromosomal mosaicism, *CFTR*, *FMR1*, Y-deletions	GINF	Case scenario	1	395
Interpretation of RNA splicing variants Interpretation of RNA analysis results to investigate the pathogenicity of splicing variants.	GRNA	Case scenario	2	255
Microdeletion syndromes[a] Prader-Willi syndrome, Angelman syndrome, Williams syndrome and Di-George syndrome	GDEL	Fixed cells/DNA	1	395
Mitochondrial disease Mitochondrial and *POLG*-related disorders	GMT	DNA	1	395
Muscular dystrophies DMD-related and other muscular dystrophies	GMD	DNA	1	395
Neurodegenerative disorders Alzheimer disease, Frontotemporal dementia, Motor neurone disease/Amyotrophic lateral sclerosis (ALS), Parkinson disease and Spinal and bulbar muscular atrophy (SBMA)	GND	DNA	1	395
Neurofibromatosis and rasopathies Neurofibromatosis (types 1 and 2), Noonan syndrome and schwannomatosis	GNF	Case scenario	1	255

External Quality Assessment (EQA)	Code	Sample	Status	£
Postnatal constitutional copy number variants (CNV) detection[a,c]	GCNV	DNA	1	471
Postnatal karyotyping[b] Structural chromosome abnormalities	GPK	Images	1	395
Primary Immunodeficiency disorders (PID) Severe Combined Immunodeficiency (SCID), Agammaglobulinaemia, Hereditary angioedema, Chronic granulomatous disease and Hyper IgE syndrome	GPID	DNA	1	395
Renal disorders Haematuria, tubulointerstitial kidney disease, cystic renal disease and Alport syndrome	GREN	DNA	1	395
Respiratory disorders Pneumothorax, respiratory insufficiency, bronchiectasis (ciliopathies/PCD and surfactants) and pulmonary arterial hypertension	GRESP	DNA	1	395
Skeletal dysplasia (including Osteogenesis Imperfecta) *FGFR2/FGFR3* related disorders, Osteogenesis Imperfecta and other skeletal dysplasias	GSKEL	DNA	1	395
Trio sequencing – postnatal (neonatal and paediatric)[a] Trio exome analysis for a postnatal scenario	GEXO	DNA	2	395
Variant validation[a] Validation of variants (SNV and CNV) detected on a research basis and associated family studies	GVAL	DNA	1	395
X-inactivation Determination of X-inactivation ratios	GXI	DNA	1	395

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[a] Suitable for molecular and cytogenomic testing (including Clinical Pathway EQAs)
[b] Suitable for cytogenomic testing only
[c] Provided in collaboration with EMQN
£: standard cost

Haematological Neoplasms

Enrol in 3 accredited Haematological Neoplasms EQAs (HAAL, HCLLC, HCLLI, HCLLT, HTF, HLYM, HMD, HMM) and get Classification of Haematological neoplasm variants EQA (VHC) for FREE!

External Quality Assessment (EQA)	Code	Sample	Status	£
Acute Lymphoblastic Leukaemia (ALL) Images for G-band chromosome and FISH analysis, DNA for whole genome copy number analysis	HALL	DNA / Images	1	395
Chronic Lymphocytic Leukaemia (CLL) Images for G-band chromosome and FISH analysis. whole genome copy number analysis	HCLLC	DNA / Fixed cells / Images	1	395
Chronic Lymphocytic Leukaemia (CLL) *IGHV* mutation status[d]	HCLLI	DNA / cDNA / lyophilised cells	1	395
Chronic Lymphocytic Leukaemia (CLL) *TP53* analysis[d]	HCLLT	DNA	1	395
Haematological Technical FISH AML, CML, ALL, MDS, MPN	HTF	Fixed cells	1	395
Lymphoma Images for G-band chromosome and supplementary FISH analysis. Fixed cells and FFPE for FISH analysis	HLYM	Fixed cells / FFPE / Images	1	395
Lymphoma Technical NGS SNVs/CNVs/fusions associated with lymphoma	HLYT	FFPE	3	215
Myeloid disorders Images G-band chromosome and FISH analysis. whole genome copy number analysis	HMD	DNA/ Images	1	395
Myeloma Images and fixed cells for FISH analysis and DNA for whole genome copy number analysis	HMM	DNA / Fixed cells / Images	1	395

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[d]Provided in collaboration with UKNEQAS LI.
£: standard cost

Molecular Newborn Screening

External Quality Assessment (EQA)	Code	Sample	Status	£
Cystic fibrosis (CF) *CFTR* variants	NBSC	Neonatal screening cards	1	875
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) c.985A>G p.(Lys329Glu) variant only	NBSM	Neonatal screening cards	1	875
Severe Combined Immunodeficiency (SCID) T-cell Receptor Excision Circles (TRECs)	NBST	Neonatal screening cards	2	875
Spinal Muscular Atrophy (SMA) *SMN1* deletion	NBSS	Neonatal screening cards	2	875

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
£: standard cost

Molecular Pathology

Enrol in a Colorectal cancer (TCRC, TCMMR), Melanoma (TM) and a Lung cancer EQA (TLE, TLCM, TLFM, TLFF)
and get Classification of Somatic solid tumour variants EQA (VSC) for FREE!

External Quality Assessment (EQA)	Code	Sample	Status	£
BRCA testing for ovarian and prostate cancer - somatic[c]	TBS	FFPE	1	285
BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline[c]	TBG	Germline DNA	1	285
BRCA testing for prostate cancer - cfDNA[c]	TBP	Artificial plasma	3	285
Breast cancer UPDATED *PIK3CA* and *ESR1*	TBCP	FFPE / ctDNA	1	280
Breast Cancer - tumour expression profiling	TEP	FFPE	3	220
Central Nervous System (CNS) tumours UPDATED 1p/19q co-deletion status, *MGMT* promoter methylation, IDH1/IDH2 status and methylation profiling	TCNS	FFPE	1	395
Cholangiocarcinoma *FGFR2* fusions and/or *IDH1* hotspots	TCC	FFPE	2	395
Circulating free (cf) DNA in lung cancer *EGFR, KRAS*	TCFD	Artificial plasma	1	285
Colorectal cancer - core *KRAS*, *NRAS* and *BRAF*	TCRC	FFPE	1	700
Colorectal cancer - MMR (MSI) UPDATED *KRAS*, *NRAS, BRAF, PLD1, MLH1, POLE, PMS2, MSH2, MSH6,* MSI and *MLH1* promoter methylation	TCMMR	FFPE	1	835
Endometrial tumours MSI, *MLH1* promoter methylation, *POLE* and *P53*	TET	FFPE	2	395
Gastrointestinal stromal tumours (GIST) *KIT* and *PDGFRA*	TGT	FFPE	1	280
Homologous recombination repair (HRD) testing NEW	THRD	FFPE	3	100
Lung cancer - comprehensive (molecular) *EGFR, KRAS, BRAF, PIK3CA, ERBB2,* MET exon 14 skipping (DNA only), *TP53, STK11 and KEAP1*	TLCM	FFPE	1	835
Lung cancer - *EGFR*	TLE	FFPE	1	700
Lung cancer - fusions (FISH/IHC) *ALK, ROS1, RET, MET* (amplification)	TLFF	FFPE	1	280
Lung cancer - fusions (molecular) *ALK, ROS1, RET, MET* (amplification and exon 14 skipping)	TLFM	FFPE	1	700

For full details of all EQA offered go to www.genqa.org/eqa
Please browse this directory and contact us at info@genqa.org if you require any further information.

Molecular Pathology

External Quality Assessment (EQA)	Code	Sample	Status	£
Melanoma *BRAF, KIT +/- NRAS*	TM	FFPE	1	700
Microsatellite Instability (MSI) MSI, *BRAF, MLH1* promoter methylation	TMSI	FFPE	1	280
Molecular Tissue identification	TMT	FFPE	1	280
NTRK fusions	TNTRK	FFPE	1	280
Renal tumours *TFE3* rearrangements	TRT	FFPE	1	280
Sarcoma	TSA	FFPE	1	280
Thyroid cancer *HRAS, NRAS, KRAS, BRAF, RET, TP53, TERT* promoter	TT	FFPE	1	280

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[c]Provided in collaboration with EMQN
£: standard cost

Multidisciplinary working (MDT)

External Quality Assessment (EQA)	Code	Sample	Status	£
Genomic molecular tumour board (MTB) for lung cancer Interpretation of test results pre and post MDT and submission of a laboratory report.	MMTB	Case scenario	3	215
Genomic multidisciplinary team (MDT) working for rare disease Interpretation of rare and inherited disease genomic test results pre and post MDT and submission of a laboratory report.	MMDTR	Case scenario	3	215

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
£: standard cost

Pharmacogenomics

Enrol in one Pharmacogenomics EQA (PGXA, PGXD, PGXT, PGXE, PGXC) – get panel EQA (PGXP) for FREE!

External Quality Assessment (EQA)	Code	Sample	Status	£
Pharmacogenomics: Aminoglycoside ototoxicity Includes m.1555A>G, m.1095T>C and m.1494C>T variants	PGXA	DNA	1	395
Pharmacogenomics: *APOE* NEW *APOE* variants	PGXE	DNA	3	100
Pharmacogenomics: *CYP2C19* *CYP2C19* variants	PGXC	DNA	3	215
Pharmacogenomics: *DPYD* *DPYD* variants	PGXD	DNA	1	395
Pharmacogenomics: panel *CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, fVl, NUDT15, SLCO1B1, TPMT, UGT1A1* and *VKORC1*	PGXP	DNA	3	215
Pharmacogenomics: *TPMT and NUDT15* *TPMT* and *NUDT15* variants	PGXT	DNA	2	395

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
£: standard cost

Preimplantation Genetic Testing (PGT)

Enrol in 3 PGT EQAs (PGTA, PGTBF, PGTM, PGTSR)
and get one at half price!

External Quality Assessment (EQA)	Code	Sample	Status	£
PGT of blastomere (FISH) Structural rearrangements <10Mb	PGTBF	Images	1	395
PGT for aneuploidies (PGT-A)	PGTA	DNA	1	395
PGT for monogenic disorders (PGT-M)[e] Cystic fibrosis (CF)	PGTM	DNA / Cells	1	395
PGT for structural rearrangements (PGT-SR) Structural rearrangements <10Mb	PGTSR	DNA	1	395

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[e]If your laboratory is unable to perform Stage 2, then the cost of Stage 2 (£260) will be refunded.
£: standard cost

Reproductive Genomics

Enrol in 3 accredited Reproductive Genomics EQAs (RMCC, NIPTA, NIPTM, NIPTS, RNPL, RCNV, RK, RRA) and get one at half price!

External Quality Assessment (EQA)	Code	Sample	Status	£
Maternal cell contamination (MCC) and fetal sexing Molecular DNA sexing and determination of level of maternal cell contamination.	RMCC	DNA	1	395
Non-invasive prenatal testing (NIPT) for aneuploidies[c] Chromosomal aneuploidies for 13, 18, 21, X and Y and fetal sexing	NIPTA	Plasma	1	471
Non-invasive prenatal testing (NIPT) for common microdeletions Angelman syndrome (AS), Di-George syndrome, Prader Willi syndrome (PWS), Williams syndrome	NIPTM	Plasma	1	395
Non-invasive prenatal testing (NIPT) for fetal sexing[c]	NIPTS	Plasma	1	471
Pregnancy loss Images for G-band chromosome and FISH analysis, DNA for whole genome analysis and targeted aneuploidy	RNPL	Images/ DNA	1	395
Prenatal constitutional Copy Number Variant (CNV) detection Whole genome analysis	RCNV	DNA	1	395
Prenatal karyotyping Images for G-band chromosome and FISH analysis	RK	Images	1	395
Rapid prenatal testing for common aneuploidies Chromosomal aneuploidies for 13, 18, 21, X and Y and fetal sexing	RRA	Fixed cell suspension / DNA	1	395
Reproductive carrier screening Molecular testing for preconception carrier screening	RPCS	DNA	3	215
Trio sequencing – prenatal Trio exome analysis for a prenatal scenario	REXE	DNA	2	395

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[c]Provided in collaboration with EMQN
£: standard cost

For full details of all EQA offered go to www.genqa.org/eqa
Please browse this directory and contact us at info@genqa.org if you require any further information.

Sample Handling

External Quality Assessment (EQA)	Code	Sample	Status	£
cfDNA extraction from plasma - somatic	DNAC	Artificial plasma	3	100
DNA extraction from blood for long read sequencing (LRS)	DNAL	Blood	3	100
DNA extraction from formalin-fixed paraffin embedded (FFPE) tissue	DNAP	FFPE	1	620
DNA extraction from fresh tissue	DNAF	Fresh tissue	2	620
DNA extraction from saliva	DNAS	Saliva	2	620
DNA extraction from venous blood	DNAB	Blood	1	1140
DNA quantification Measurement of DNA concentration	DNAQ	DNA	2	360

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
£: standard cost

Technical

Enrol in an NGS EQA (NGSG, NGST, NGSGC or NGSM)
and get a Classification of SNV/CNVs EQA (VGC, VGI, VCNVG) for FREE!

External Quality Assessment (EQA)	Code	Sample	Status	£
Next Generation Sequencing (NGS) for germline CNVs[c] CNVs ≥50bp	NGSGC	Germline DNA	3	505
Next Generation Sequencing (NGS) for germline SNVs and indels[c] NGS of single genes, panels, exomes and whole genomes (Indels <50bp)	NGSG	Germline DNA	1	715
Next Generation Sequencing (NGS) for somatic SNVs and indels – tumour testing only[c] NGS of hot spot panels (Indels <50bp)	NGST	Tumour DNA	2	715
Next Generation Sequencing (NGS) for somatic SNVs and indels – tumour with germline subtraction analysis[c] NGS and germline subtraction (Indels <50bp)	NGSM	Matched tumour and germline DNA	2	1115
Optical Genome Mapping - haematological neoplasms UPDATED	OGMH	Data files	3	215
Optical Genome Mapping - rare disease UPDATED	OGMR	Data files	3	215

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[c]Provided in collaboration with EMQN
£: standard cost

Variant Classification & Nomenclature

External Quality Assessment (EQA)	Code	Sample	Status	£
Classification and interpretation of germline CNVs UPDATED CNVs ≥50bp	VCNVG	Case scenario	2	260
Classification and interpretation of germline SNVs and indels indels <50bp	VGI	Case scenario	1	260
Classification of germline SNVs and indels indels <50bp	VGC	Case scenario	1	260
Classification of haematological neoplasm SNVs, CNVs and SVs CNVs ≥50bp	VHC	Case scenario	3	260
Classification of somatic solid tumour SNVs, CNVs and SVs CNVs ≥50bp	VSC	Case scenario	3	260
ISCN (International System for Human Cytogenomic Nomenclature) Determine the correct ISCN for the abnormalities described	VISCN	Case scenario	3	260

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
£: standard cost

Viral Sequencing

External Quality Assessment (EQA)	Code	Sample	Status
SARS-CoV-2 sequencing[f]	SCOV	Freeze-dried inactivated SARS-CoV-2	3

Status: EQA ISO 17043 status (Accredited = 1, Not accredited = 2, Pilot = 3)
[f]Provided in collaboration with UKNEQAS for Microbiology. Participants will be required to register with UK NEQAS for Microbiology for the 2024 EQA (a GenQA account will then be created). All invoicing and shipment costs will be via UK NEQAS for Microbiology

Individual Competency Assessment

Showcase your genomic knowledge and commitment to continued professional development with GENie - the individual learning and assessment tool from GenQA. Offering a comprehensive suite of training modules tailored to a wide range of specialties and skills, this online training platform gives you the chance to showcase your expertise and illustrate your commitment to continued professional development.

Assessment		Availability	Type	Fee
BRCA and HRR gene variant classification	GENie GENOMIC ONLINE INDIVIDUAL EDUCATION See **www.genqa.org/genie**	April October	Educational	0[4]
Germline SNV classification		Continuous	Educational Variant assessment module	£330 for 10 users[$]
Germline CNV classification				
HGVS nomenclature		Trial version available	Educational nomenclature assessment module	0[5]
ISCN nomenclature				

GENie prices valid from 1st January 2025

[4]Sponsored by AstraZeneca

[$]£330 for up to 10 user licences per year, £550 for 11-20 licences and £253 per additional 10 licences per year. Individuals can also purchase for £35 per year.

[5] When the continuous modules become available in 2025, the cost will be £330 for up to 10 user licences per year, £550 for 11-20 licences and £233 per additional 10 licences per year. Individuals can also purchase for £35 per year.

Tumour Content Assessment:

Assessment		Availability	Type	Fee
Tumour content estimation and annotation of tissue samples	Tissue-I Individual online competency assessment See **https://genqa.org/tissuei**	Spring Autumn	Educational only	565 for 3 users

Version 2: 8th October 2024 – 2025TPS EQA cost updated

Version 2: 23rd October 2024 – 2025GDSD EQA updated (sample withdrawn)